Product news

Share this content:
Canadian regulators have approved Novartis' Diovan (valsartan) to treat chronic heart failure in patients who cannot tolerate angiotensin-converting-enzyme (ACE)  inhibitors, a common type of heart failure therapy.   
Share this content:
Scroll down to see the next article